Earlier this week, it was reported in the Economic Times that the Delhi High Court has refused US pharma major Bristol-Myers Squibb’s application for an ex-parte injunction order against Ranbaxy for launching a generic version of Squibb’s hepatitis B drug, Baraclude. However, the application for interim injunction is yet to be heard.
The Court has given Ranbaxy a period of 2 weeks to file its reply after which arguments on the interim application would be taken up. The drug Entecavir reportedly has global sales to the tune of $ 191 million.The Court observed that Squibb’s patented molecule appeared to be a pre-1995 one.
Apart from Ranbaxy, Natco and Cipla too seem to have plans in the pipeline for launching generic versions of Baraclude.
This matter promises to be an interesting one, watch out this space for more updates.